Tin tức & Cập nhật

Empagliflozin improves outcomes in HFpEF patients regardless of age
Empagliflozin improves outcomes in HFpEF patients regardless of age
06 Jul 2022 bởiStephen Padilla

Treatment with empagliflozin results in a reduction in heart failure (HF) risk and renal outcomes and in better health-related quality of life (HRQoL) among patients with chronic HF with preserved ejection fraction (HFpEF), a study has shown. In addition, the study drug is well tolerated by older patients.

Empagliflozin improves outcomes in HFpEF patients regardless of age
06 Jul 2022
Cardiovascular events not uncommon in ICU-admitted COVID-19 survivors
Cardiovascular events not uncommon in ICU-admitted COVID-19 survivors
06 Jul 2022

One out of five severe COVID-19 survivors who underwent mechanical ventilation have coronary artery disease (CAD), a quarter have subclinical left ventricular dysfunction defined as reduced echocardiographic global longitudinal strain (GLS), and 42 percent have cardiac magnetic resonance (CMR) abnormalities, reports a study.

Cardiovascular events not uncommon in ICU-admitted COVID-19 survivors
06 Jul 2022
Poor mental health tied to worse prognosis, outcomes in IBD
Poor mental health tied to worse prognosis, outcomes in IBD
06 Jul 2022
Vedolizumab appears safe, effective in first-line treatment of ulcerative colitis in children
Vedolizumab appears safe, effective in first-line treatment of ulcerative colitis in children
06 Jul 2022

Children with ulcerative colitis seem to respond well to vedolizumab in the first-line setting, inducing remission without increasing the risk of adverse events, according to a small study.

Vedolizumab appears safe, effective in first-line treatment of ulcerative colitis in children
06 Jul 2022